Patients’ responses to oncologists can help predict survival in chronic lymphocytic leukemia
Patients’ responses to questions routinely raised by oncologists may provide important clues about their chances of survival from…
Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously…
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
This Research Article, published in Future Oncology, provides a detailed comparison of zanubrutinib and acalabrutinib for relapsed/refractory chronic…